	Page 1	
1	UNITED STATES PATENT AND TRADEMARK OFFICE	
2	BEFORE THE PATENT TRIAL AND APPEAL BOARD	
3		
4	MYLAN PHARMACEUTICALS, INC.,) CASE IPR2021-00880	
5	CELLTRION, INC., and APOTEX, INC.,) Patent 9,669,069 B2	
6	Petitioners,)	
7	vs.) CASE IPR2021-00881	
8	REGENERON PHARMACEUTICALS, INC.,) Patent 9,254,338 B2	
9	Patent Owner)	
10) CONFIDENTIAL	
11		
12	VIDEO DEPOSITION OF ALEXANDER M. KLIBANOV, PH.D.	
13	MARCH 24, 2022	
14		
15	Reported by: Rosalie A. Kramm, CSR No. 5469, CRR	
16		
17		
18		
19		
20		
21		
22		
23		
24		
25		

Veritext Legal Solutions

www.veritext.com 888-391-3376



Page 2	Page 4
1 APPEARANCES	1 INDEX (continued)
2	2
3 FOR THE PETITIONER:	3 DEPOSITION EXHIBIT: PAGE
4 RAKOCZY MOLINO MAZZOCHI SIWIK	4 Exhibit 9 - CAS registry for No 862111-32-8 103
5 BY: NEIL B. McLAUGHLIN, PH.D., ESQ.	5 Exhibit 10 - 10-Q 1, Regeneron_10q htm QUARTERLY 106
6 BY: HEINZ J. SALMEN, ESQ.	6 REPORT
7 BY: THOMAS H. EHRICH, ESQ.	7 Exhibit 11 - Article, "VEGF Trap-Eye for the 112
8 Six West Hubbard Street	8 treatment of neovascular age-related
9 Chicago, Illinois 60654	9 macular degeneration"
10 312.222.7241	10 Exhibit 12 - Article, "VEGF Trap complex 127
11 nmclaughlin@rmmslegal.com	11 formulation measures production rates
12 hsalmen@rmmslegal.com	12 of VEGF, providing a biomarker for
13 tehrich@rmmslegal.com	13 predicting efficacious angiogenic
14	14 blockade"
15 FOR THE PATENT OWNER:	15 Exhibit 13 - Article, "VEGF Trap induces 129
16 ARNOLD & PORTER	antiglioma effect at different stages
17 BY: JEREMY COBB, ESQ.	17 of disease"
18 601 Massachusetts Avenue, NW	18 Exhibit 14 - Article, "Inhibition of Vascular 134
19 Washington, DC 20001-3743	19 Endothelial Growth Factor in the
20 202.942.6828	20 Primate Ovary Up-Regulates
21 jeremy.cobb@arnoldporter.com	21 Hypoxia-Inducible Factor 1 alpha in
22	the Follicle and Corpus Luteum"
23 ALSO PRESENT: ELAINE WOO	23 Exhibit 15 - U S Patent No 7,374,758 B2 137
24 ALSO PRESENT: STEPHEN GAUDET	24 Exhibit 16 - APPLICATION FOR EXTENSION OF PATENT 141
25 THE VIDEOGRAPHER: KEVIN MONTGOMERY	Y 25 TERM UNDER 35 U S C, Section 156"
Page 3	Page 5
1 INDEX	1 INDEX (continued)
2	2
3 EXAMINATION PAGE	3 DEPOSITION EXHIBIT: PAGE
4 BY MR. McLAUGHLIN 9	4 Exhibit 17 - Article, "A Phase I study of 160
5	5 Intravitreal Vascular Endothelial
6 DEPOSITION EXHIBIT: PAGE	6 Growth Factor Trap-Eye in Patients
7 Exhibit 1 - Expert Declaration of 10	7 with Neovascular Age-Related Macular
8 Alexander M. Klibanov, Ph.D.	8 Degeneration"
9 Exhibit 2 - Curriculum Vitae of Alexander M. 10	9 Exhibit 18 - Excerpt from journal Eye, Volume 29, 164
10 Klibanov	10 pages 293 to 293
11 Exhibit 3 - Declaration of Alexander M. Klibanov, 24	11 Exhibit 19 - Article, "Increase of Plasma VEGF 166
12 Ph.D., in Support of Defendants'	12 after Intravenous Administration of
13 Opposition to Amgen's Infringement	13 Bevacizumab Is Predicted by a
14 Motion for Summary Judgment of	14 Pharmacokinetic Model"
15 Infringement of '422 Claim 1, '933	15 Exhibit 20 - Article, "Comparison of binding 168
16 Claim 3, and '698 Claim 6	16 characteristics and in vitro
17 Exhibit 4 - Article, VEGF-Trap: A VEGF blocker 41	17 activities of three inhibitors of
18 with potent antitumor effects	vascular endothelial growth factor A"
19 Exhibit 5 - U.S. Patent 7,531,173 B2 - Ophthalmic 60	19 Exhibit 21 - Article, "A novel engineered VEGF 169
20 Composition of a VEGF Antagonist	20 blocker with an excellent
21 Exhibit 6 - Alignment of amino acid sequences of 64	21 pharmacokinetic profile and robust
22 SEQ. ID No:2 of the '173 patent	22 antitumor activity"
23 Exhibit 7 - U.S. Patent 9,254,338 B2 67	23 Exhibit 22 - WHO Drug Information," Volume 20, 179
24 Exhibit 8 - Article, "Aflibercept"; from Adis 72	24 No. 2, 2006
25 R&D Profile	25 //
	

2 (Pages 2 - 5)

Veritext Legal Solutions

888-391-3376




www.veritext.com


	T
Page 6	Page 8
1 I N D E X (continued)	1 everyone attending remotely will now state their
2	2 appearances and affiliations for the record.
3 DEPOSITION EXHIBIT: PAGE	3 If there are any objections to proceeding,
4 Exhibit 23 - Alignment conducted using SEQ. 182	4 please state them at the time of your appearance,
5 ID No:2 in the '338 patent	5 beginning with the noticing attorney.
6 Exhibit 24 - Textbook, "Biochemistry" 187	6 MR. McLAUGHLIN: Neil McLaughlin from the Lav
7 Exhibit 25 - Article, "Lessons learned from 190	7 Offices of Rakoczy Molino Mazzochi Siwik on behalf of
8 biosimilar epoetins and insulins"	8 Petitioners, Mylan Pharmaceuticals, Inc.
9 Exhibit 26 - Slide deck, "Zaltrap Non-Comparability 198	9 MR. COBB: Jeremy Cobb with Arnold & Porter on
10 Issue"	10 behalf of Patent Owner, Regeneron.
11	MS. WOO: Eileen Woo from Regeneron.
12	THE REPORTER: People on the phone, please?
13	MR. GAUDET: Stephen Gaudet from Regeneron.
14	MR. SALMEN: Hi, this is Heinz Salmen of
15	15 Rakoczy Molino Mazzochi Siwik on behalf of Petitioner,
16	16 Mylan.
17	MR. EHRICH: Thomas Ehrich of Rakoczy Molino
18	18 Mazzochi Siwik on behalf of Petitioner Mylan
19	19 Pharmaceuticals, Incorporated.
20	THE VIDEOTAPE OPERATOR: At this time, the
21	21 court reporter will now swear in the witness.
22	
23	23
24	24
25	25 //
Page 7	Page 9
1 MARCH 24, 2022 9:47 A M THURSDAY SAN DIEGO, CALIFORNIA	1 ALEXANDER M. KLIBANOV,
2 THE VIDEOTAPE OPERATOR: Good morning We are	2 having been first duly sworn, testified as follows:
3 now on the record at 9:47 a m on March 24th, 2022	3
4 Please note that the microphones are sensitive and may	4 EXAMINATION
5 pick up whispering, private conversations, and cellular	5 BY MR. McLAUGHLIN:
6 interference Please turn off all cell phones or place	6 Q. Dr. Klibanov, how many times have you been
7 them away from the microphones as they can interfere with	7 deposed?
8 the deposition audio Audio and video recording will	8 A. Good morning, Mr. McLaughlin.
9 continue to take place unless all parties agree to go off	9 I would say over the last 25, 30 years, maybe
10 the record	10 three dozen times.
This is Media Unit 1 of the Video Recorded	Q. And how many of those were patent cases?
12 Deposition of Alexander Klibanov, Ph D in the matter of	12 A. You'll have to slow down, Mr. McLaughlin.
13 Mylan Pharmaceuticals, Incorporated, et al, vs	13 Could you repeat your question slower, please?
14 Regeneron Pharmaceuticals, Incorporated, et al, filed in	Q. How many of those cases were patent cases?
15 the United States Patent and Trademark Office, before the	15 A. The vast majority of them.
16 Patent and Appeal Board, Case Nos IPR02021-00880 and IPR	Q. How many of those were you deposed on behalf of
17 2021-00881	17 the patentee?
This deposition is taking place at Fish &	18 A. I don't know. I've been deposed in cases, both
19 Richardson, located at 122860 El Camino Real, Suite 400,	19 on behalf of patent holders and on behalf of patent
20 San Diego, California 92130 My name is Kevin Montgomery	20 challengers, but I don't know what the breakdown is.
21 from the firm Veritext, and I'm the videographer The	Q. You don't recall sitting here today how many
22 court reporter is Rosalie Kramm from the firm Veritext	22 times you've testified on behalf of patentees?
	00 4 551 1 1 1 7 11
23 I am not related to any party in this action, nor am I 24 financially interested in the outcome	 A. That's what I said. Once again, you'll have to slow down, sir.

3 (Pages 6 - 9)

Q. How much time did you spend prepping for



25





Counsel and all present in the room and

Page 10

- 1 today's deposition?
- 2 A. Several hours.
- 3 Q. Approximately how many?
- 4 A. All together, maybe close to ten.
- 5 Q. Was that over the course of a single day or
- 6 multiple days?
- 7 A. Multiple days.
- Q. Which days were those? 8
- A. Yesterday, the day before yesterday, and also a
- 10 few hours last week.
- 11 (Exhibit 1 was marked for identification.)
- 12 MR. McLAUGHLIN: Dr. Klibanov, I'm going to be
- 13 handing you what has been marked as Exhibit 1.
- 14 (Exhibit 2 was marked for identification.)
- 15 MR. McLAUGHLIN: I'm also going to be handing
- 16 you what has been marked as Exhibit 2.
- 17 THE WITNESS: Thank you.
- 18 BY MR. McLAUGHLIN:
- Q. So Exhibit 1 is the Expert Declaration of
- 20 Alexander M. Klibanov Ph.D. Exhibit 2409. And this copy
- 21 is from IPR 2021-00881.
- 22 Did you submit identical declarations in both
- 23 of these matters, Dr. Klibanov?

1 copy of my curriculum vitae.

- A. I cannot possibly say they are identical, but I
- 25 did submit an expert declaration, and I did provide a

- 1 that time?
- A. Yes, I published another paper that appeared in

Page 12

Page 13

- 3 2091 -- sorry, 2021, another paper.
 - Q. Okay. Then if you flip to page 42, it also
- 5 appears the last invited presentation is also 2017; is
- 6 that correct?
- A. Correct.
- Q. Have there been any further invited
- presentations since that time?
- 10 A. No, I have not given any more presentations.
- 11 Q. So flipping back to page 24, you said you have
- 12 some additional publications since 2017.
- 13 A. I did not say that.
- 14 Q. I believe you mentioned one or two additional
- 15 publications.
 - A. I mentioned an additional publication.
- 17 Q. So there has only been once since 2017?
- 18 A. As far as I recall, yes. I published in 2021.
- 19 Q. Do you recall the subject matter of that
- 20 publication?
- A. Yes, and I mean I -- it was a use of our -- the
- 22 technology that was developed in my laboratory at MIT for
- 23 using antimicrobial materials, and I want to say that it
- 24 was for the treatment of an eye disease, but I do not
- 25 recall for sure.

- Page 11
- Q. Okay. And on the cover of your declaration you
- 3 see there are two case matter numbers there.
- A. Yes.
- 5 O. One ends in 880. The other ends in 881.
- 6 A. Correct.
- 7 Q. Now, if you flip to the back, page 52, is that
- 8 your signature?
- 9 A. It's a facsimile of my signature, yes.
- 10 (Exhibit 2 was marked for identification.)
- 11 BY MR. McLAUGHLIN:
- Q. Exhibit 2 is the curriculum vitae of Alexander 12
- 13 M. Klibanov, IPR Exhibit No. 2082.
- 14 Do you see that?
- 15 A. I do see that.
- 16 Q. Is this CV up-to-date?
- 17 A. It was up-to-date to the best of my ability at
- 18 the time when I submitted it.
- 19 Q. So if you flip to page 24 --
- 20 A. Okay.
- 21 Q. -- it appears that the last entry there or the
- 22 last few entries, I should say, are publications from
- 23 2017.
- 24 A. Go ahead, please.

www.veritext.com

25 Q. Have there been any further publications since

- Q. Do you know which eye disease? 1
- 2 A. As I just said, I don't recall for sure.
- Q. Do you know if it would have been an angiogenic
- 4 eye disorder?
- A. As I said, I don't recall for sure.
- Q. If you could flip back to Deposition
- 7 Exhibit No. 1, this is your declaration from these
- 8 matters. And if you could flip to paragraph 21, please.
- 9 A. Okay.
- 10 O. Here you set forth Patent Owner's definition of
- 11 a person of ordinary skill in the art, correct?
- 12 A. Well, I wouldn't put it quite that way.
- 13 Q. How would you put it?
- 14 A. I mean, there is just a single sentence in this
- 15 paragraph 21, which says, "I understand that Patent Owner
- 16 contends that the skilled artisan is an ophthalmologist
- 17 with experience in treating angiogenic eye disorders,
- 18 including through the use of VEGF antagonists." That's
- what it says.
- 20 Q. You're not a person of ordinary skill in the
- 21 art under the Patent Owner's definition, correct?
- 22 A. Say it again slowly, please.
- 23 Q. You are not a person of ordinary skill in the
- 24 art under the Patent Owner's definition, correct?
 - A. Well, my area of expertise is brought in

4 (Pages 10 - 13)

Veritext Legal Solutions

888-391-3376



2

3

4

11

13

15

17

18

22

25

10 I'm offering.

12 ophthalmologist --

16 disorders, correct?

14 BY MR. McLAUGHLIN:

for me to characterize them.

21 BY MR. McLAUGHLIN:

- 1 chemistry, structure by chemistry. That's what my
- 2 declaration is about. These are the issues that I
- 3 testify on in my declaration.
- 4 I'm not a clinician. I have published a number
- 5 of papers on treating of eye disease. I have
- 6 collaborated with -- collaborated with ophthalmologists
- 7 on a number of occasions as evidenced by my publications.
- 8 I've reviewed papers, grant proposals in these areas. So
- 9 that's my experience specifically in the area of
- 10 ophthalmology.
- Q. So is that a no? You are not a person of
- 12 ordinary skill in the art under the Patent Owner's
- 13 definition?
- 14 A. I could not answer it with a "yes" or "no,"
- 15 because I don't think that it's -- it would be
- 16 appropriate. I can repeat what I just said, if you want
- 17 me to.
- 18 Q. No, no need.
- 19 A. Okay.
- 20 Q. You are not an ophthalmologist with experience
- 21 in treating angiogenic eye disorders, correct?
- A. Yes, I am not -- that is correct. Yes. I -- I
- 23 probably fall under the person of ordinary skill in the
- 24 art definition put forth by petitioner. In fact, I
- 25 definitely do. But I'm not a practicing ophthalmologist,
 - Page 15

Page 17

- 1 nor are the issues that I have opined on in my
- 2 declaration deal with practicing ophthalmology.
- Q. So if you could turn to paragraph 41, please.
- 4
- 5 Q. I'm sorry. Page 41 of your declaration.
- A. Okay. I'm on page 41.
- Q. There is a heading on that page regarding, 7
- 8 "Knowledge of the Amino Acid Sequence of VEGF Trap-Eye
- 9 Alone Would Not Necessarily Result in Treatment."
- 10 Do you see that?
- 11 A. I do see that.
- 12 Q. And further down in that first paragraph,
- 13 paragraph 90, underneath that heading, you have a phrase
- 14 there about treating an angiogenic eye disorder.
- 15 A. Mr. McLaughlin, I'd like to establish for the
- 16 routine that when you direct my attention to a particular
- 17 paragraph, in my declaration, I first would like to read
- 18 it to myself, and maybe a little more to orient myself.
- 19 And then I'll be happy to entertain your questions. Is
- Q. For right now I'm just asking you about this
- 22 phrase that's in quotes, "treating the angiogenic eye
- 23 disorder."
- A. I still would like to read the paragraph to
- 25 myself.

www.veritext.com

- 1 scientific developments and have for many years, but I

23 Trap-Eye -- VEGF Trap-Eye as it was going through

A. I don't remember. I followed a lot of

24 clinical trials in the 2008, 2010 time frame?

Q. Sure. Go ahead. Read that paragraph.

Okay. I read that paragraph to myself.

5 and treating an angiogenic eye disorder from the

Q. So you're not offering opinions about treatment

6 perspective of an ophthalmologist experienced in treating

A. The opinions that I offer are what is found in

Q. And that does not include the perspective of an

Q. -- with experience in treating angiogenic eye

are those that are in my declaration, and I see no reason

Q. Were you following the development of VEGF

MR. COBB: Objection. Asked and answered.

THE WITNESS: As I said, the opinions I offered

9 the four corners of my expert declaration. That's what

A. Thank you, sir.

7 angiogenic eye disorders, correct?

MR. COBB: Objection.

- 2 don't specifically recall.
- Q. Do you have experience working with recombinant
- 4 VEGF receptor fusion proteins?
- A. I have a lot of experience in working with
- 6 recombinant proteins, including antibodies. I'm not
- 7 specifically sure about VEGF types of proteins.
- Q. Have you ever been involved in the development
- 9 of a VEGF fusion protein for use as a therapeutic?
- 10 A. I don't believe so, but I'm not sure.
- 11 Q. Have you ever been involved in the design of a
- 12 purification process for a commercial VEGF receptor
- 13 fusion protein?
- A. I have been involved in designing lot of
- 15 purification schemes for pharmaceutical proteins of
- 16 different types. But I'm not sure about this particular
- 17 type of protein.
- Q. So sitting here today, you don't recall having
- 19 been involved in the design of a purification process for
- 20 commercial VEGF receptor fusion proteins?
- A. Mr. McLaughlin, you will have to slow down.
- 22 Unless you want me to preface every answer I give you
- 23 with the request that you slow down, you may want to
- 24 monitor yourself.
- Q. Are you having trouble understanding me today,

5 (Pages 14 - 17)

Veritext Legal Solutions

888-391-3376



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

